Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Retatrutide is an investigational once-weekly triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide and tirzepatide
Lower circulating insulin levels and lower IR in PWS compared to obese controls were described in most studies, but a few exceptions existed
Attenuated but clinically relevant gains in event-free survival were observed in analyses assuming 50% additive effects of combination therapy, including for major adverse cardiovascular events (2.4 years [95% CI, 1.13.5]), chronic kidney disease progression (4.5 years [95% CI, 2.85.9]), and all-cause death (1.8 years [95% CI, 0.72.8])
Single-dose vials are available for $499 per month through the LillyDirect Zepbound Self Pay Journey Program, with the highest doses available beginning July 7
No cases of ION were reported for Rybelsus, the oral tablet version of semaglutide
US$ 27.27
US$ 27.53
US$ 27.67
US$ 28.95
US$ 28.34
US$ 26.43
